MultiCell Technologies Inc (MCET)

[TPX]

Penny Stock Biotech Report 2016-06-15! About OXIS, Multicell,... projects!

!!! 14-page report! PLEASE READ !!! http://fliphtml5.com/nueh/qrhz/basic

IMMEDIATE ALERT: OXIS INTERNATIONAL, INC. SYMBOL: (OXIS)EXCLUSIVE TECHNOLOGYLICENSING & MAJORMARKET POTENTIAL! OXIS has licensed exclusive rights to three Antibody-drug conjugates (ADC) through an agreement made in early 2015 with MultiCell Immunotherapeutics, Inc. (MCIT). MCIT will prepare these ADCs for further evaluation as prospective therapeutics for the treatment of triple-negative breast cancer, as well as multiple myeloma and associated osteolytic bone disease. Though OXIS is still in its infancy compared to industry giants, the potential for acquisitions or even better yet, a real market driver may not be any greater than RIGHT NOW. It doesn’t take long to look at the numbers of industry comps to show a true opportunity could be presenting itself in a BIG WAY: Multiple Myeloma Presenting Multi BILLION Dollar Opportunity?WWW.OXIS.COM

IMMEDIATE ALERT: OXIS INTERNATIONAL, INC. SYMBOL: (OXIS)SEASONED & EXPERIENCEDMANAGEMENT TEAM But no company can expect to go the distance without a sound leadership team at the helm and OXIS has just that! As CEO, Anthony Cataldo is no stranger to emerging biotech and has been credited with taking companies “to the next level”. In fact Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc., (LBIO).Mr. Cataldo created the highly successful Lion/Genesis (LBIO)with the inclusion of assets acquired from the National CancerInstitute for the treatment of stage four melanoma. Cataldomanaged to grow LBIO’s market-cap 250x through a simpleprocess: acquiring strong IP, having a strong research team, andattracting the right group of inside ownership to build a REALbiotechnology enterprise.Mr. Cataldo has extensive experiencein the biotechnology sector havingserved as Chairman/CEO of severalbiotech companies including: MultiCellTechnologies, Inc., Calypte BiomedicalCorporation, and Senetek, PLC.WWW.OXIS.COM